Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fedratinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,836Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 6Inrebic

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Inrebic

    Fedratinib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Inrebic

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Fedratinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 55

    2019 Revenue in Millions : 7

    Growth (%) : 686

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Inrebic

    Fedratinib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Inrebic

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Fedratinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 74

    2020 Revenue in Millions : 55

    Growth (%) : 35

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Inrebic

    Fedratinib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Inrebic

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Fedratinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 85

    2021 Revenue in Millions : 74

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Inrebic

    Fedratinib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Inrebic

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Fedratinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 110

    2022 Revenue in Millions : 85

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Inrebic

    Fedratinib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Inrebic

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb/Celgene

    Fedratinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 5

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Inrebic

    Fedratinib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Inrebic

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb/Celgene

    Fedratinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 2

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF